Oral Biology pp 107-123 | Cite as

Gene Therapy of Salivary Diseases

  • Bruce J. BaumEmail author
  • Sandra Afione
  • John A. Chiorini
  • Ana P. Cotrim
  • Corinne M. Goldsmith
  • Changyu Zheng
Part of the Methods in Molecular Biology book series (MIMB, volume 1537)


For many years, our research group worked to develop gene transfer approaches for salivary gland disorders that lacked effective conventional therapy. The purpose of this chapter is to describe and update key methods used in this process. As described in our original chapter from the 2010 volume, we focus on one clinical condition, irradiation-induced salivary hypofunction, and address the choice of transgene and vector to be used, the construction of recombinant viral vectors, how vector delivery is accomplished, and methods for assessing vector function in vitro and in an appropriate animal model.

Key words

Gene therapy Salivary glands Adenovirus Adeno-associated virus Radiation damage Salivary hypofunction 



The authors’ research is supported by the intramural research program of the National Institute of Dental and Craniofacial Research.


  1. 1.
    Siegel RL, Miller KD, Jemal A (2015) Cancer statistics 2015 CA. Cancer J Clin 65:5–29CrossRefGoogle Scholar
  2. 2.
    Mitsias DI, Kapsogeorgou EK, Moutsopoulos HM (2006) Sjögren’s syndrome: why autoimmune epithelitis. Oral Dis 12:523–532CrossRefPubMedGoogle Scholar
  3. 3.
    Kok MR, Yamano S, Lodde BM, Wang J, Couwenhoven RI, Yakar S, Voutetakis A, Leroith D, Schmidt M, Afione S, Pillemer SR, Tsutsui MT, Tak PP, Chiorini JA, Baum BJ (2003) Local adeno-associated virus-mediated interleukin 10 gene transfer has disease-modifying effects in a murine model of Sjögren’s syndrome. Hum Gene Ther 14:1605–1618CrossRefPubMedGoogle Scholar
  4. 4.
    Baum BJ (1993) Principles of saliva secretion. Ann NY Acad Sci 694:17–23CrossRefPubMedGoogle Scholar
  5. 5.
    Vitolo JM, Baum BJ (2002) The use of gene transfer for the protection and repair of salivary glands. Oral Dis 8:183–191CrossRefPubMedGoogle Scholar
  6. 6.
    Preston GM, Agre P (1991) Isolation of the cDNA for erythrocyte integral membrane protein of 28 kilodaltons: member of an ancient channel family. Proc Natl Acad Sci U S A 88:11110–11114CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Baum BJ, Wellner RB, Zheng C (2002) Gene transfer to salivary glands. Int Rev Cytol 213:93–146CrossRefPubMedGoogle Scholar
  8. 8.
    Mastrangeli A, O'Connell B, Aladib W, Fox PC, Baum BJ, Crystal RG (1994) Direct in vivo adenovirus-mediated gene transfer to salivary glands. Am J Physiol 266:G1146–G1155PubMedGoogle Scholar
  9. 9.
    McGrory WJ, Bautista DS, Graham FL (1988) A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. Virology 163:614–617CrossRefPubMedGoogle Scholar
  10. 10.
    Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59–74CrossRefPubMedGoogle Scholar
  11. 11.
    Chiorini JA, Wendtner CM, Urcelay E, Safer B, Hallek M, Kotin RM (1995) High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors. Hum Gene Ther 6:1531–1541CrossRefPubMedGoogle Scholar
  12. 12.
    Park JY, Lim BP, Lee K, Kim YG, Jo EC (2006) Scalable production of adeno- associated virus type 2 vectors via suspension transfection. Biotechnol Bioeng 94:416–430CrossRefPubMedGoogle Scholar
  13. 13.
    Qu G, McClelland A, Wright JF (2000) Scaling-up production of recombinant AAV vectors for clinical applications. Curr Opin Drug Discov Devel 3:750–755PubMedGoogle Scholar
  14. 14.
    Clark KR, Voulgaropoulou F, Johnson PR (1996) A stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors. Gene Ther 3:1124–1132PubMedGoogle Scholar
  15. 15.
    Conway JE, Rhys CM, Zolotukhin I, Zolotukhin S, Muzyczka N, Hayward GS, Byrne BJ (1999) High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene Ther 6:986–993CrossRefPubMedGoogle Scholar
  16. 16.
    Gao GP, Lu F, Sanmiguel JC, Tran PT, Abbas Z, Lynd KS, Marsh J, Spinner NB, Wilson JM (2002) Rep/Cap gene amplification and high-yield production of AAV in an A549 cell line expressing Rep/Cap. Mol Ther 5:644–649CrossRefPubMedGoogle Scholar
  17. 17.
    Urabe M, Ding C, Kotin RM (2002) Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum Sene Ther 13:1935–1943CrossRefGoogle Scholar
  18. 18.
    Vitolo JM, Cotrim AP, Sowers AL, Russo A, Wellner RB, Pillemer SR, Mitchell JB, Baum BJ (2004) The stable nitroxide Tempol facilitates salivary gland protection during head and neck irradiation in a mouse model. Clin Cancer Res 10:1807–1812CrossRefPubMedGoogle Scholar
  19. 19.
    Cotrim AP, Hyodo F, Matsumoto K, Sowers AL, Cook JA, Baum BJ, Krishna MC, Mitchell JB (2007) Differential radiation protection of salivary glands versus tumor by Tempol with accompanying tissue assessment of Tempol by magnetic resonance imaging. Clin Cancer Res 13:4928–4933CrossRefPubMedGoogle Scholar
  20. 20.
    Walters RW, Yi SM, Keshavjee S, Brown KE, Welsh MJ, Chiorini JA, Zabner J (2001) Binding of adeno-associated virus type 5 to 2,3-linked sialic acid is required for gene transfer. J Biol Chem 273:20610–20616CrossRefGoogle Scholar
  21. 21.
    Smith RH, Afione S, Kotin RM (2002) Transposase-mediated construction of an integrated adeno associated virus type 5 helper plasmid. Biotechniques 208:210–211Google Scholar

Copyright information

© Springer Science+Business Media LLC 2017

Authors and Affiliations

  • Bruce J. Baum
    • 1
    • 2
    Email author
  • Sandra Afione
    • 1
  • John A. Chiorini
    • 1
  • Ana P. Cotrim
    • 1
  • Corinne M. Goldsmith
    • 1
  • Changyu Zheng
    • 1
  1. 1.Molecular Physiology and Therapeutics BranchNational Institute of Dental and Craniofacial Research, National Institutes of Health (NIH)BethesdaUSA
  2. 2.Molecular Physiology and Therapeutics BranchNational Institute of Dental and Craniofacial Research, National Institutes of Health (NIH)BethesdaUSA

Personalised recommendations